Insulin A Chain (A12-21) – Other Categories

Type I diabetes is an autoimmune condition caused by the destruction of insulin-producing β cells. The initiation mechanism is unclear but involves activating autoreactive T cells against the β-cell-specific antigen, insulin. RIP-B7.1 mice express CD80 on pancreatic β cells and are a model for studying de novo induction of diabetogenic CD8 T cells. Immunization of RIP-B7.1 mice with preproinsulin (ppins)-encoding plasmid DNA induces experimental autoimmune diabetes (EAD). EAD is associated with significant induction of CD8 T cells specific for the (A12-21) restricted epitope leading to the destruction of β cells. The Insulin A Chain (A12-21) epitope is recognised by pancreas-infiltrating CD8 T cells isolated from immunized, diabetic RIP-B7.1 mice as shown by flow cytometry. The Insulin A Chain (A12-21) epitope can also be used to stimulate inducible IFN- expression of ppins-primed CD8 T cells ex vivo as determined by flow cytometry. GFP fusion has shown the expression of insulin A chain (A12-21) epitope in HeLa cells.

 

Technical specification

 KD20 peptide Sequence : H-SLYQLENYCN-OH
 KD20 peptide MW : 1.246.3 g/mol
 KD20 peptide Purity : > 95%
 KD20 peptide Counter-Ion : TFA Salts
Peptide library synthesis KD20 peptide Delivery format : Lyophilized

Price

 

Product Size Price €
Price $
CRB1000415-0.5 mg 0.5 mg 141 € 113 $
CRB1000415-1 mg 1 mg 193 € 154 $
CRB1000415-
CRB1000415-
CRB1000415-

For Bulk Orders